Precigen (PGEN) Competitors

Cellectis (NASDAQ:CLLS) and Precigen (NASDAQ:PGEN) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, community ranking, dividends, analyst recommendations, institutional ownership, earnings and risk.

Do institutionals & insiders believe in CLLS or PGEN?

63.9% of Cellectis shares are held by institutional investors. Comparatively, 33.5% of Precigen shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 44.9% of Precigen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Is CLLS or PGEN more profitable?

Cellectis has a net margin of -401.83% compared to Precigen's net margin of -3,084.55%. Cellectis' return on equity of -78.90% beat Precigen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-401.83%	-78.90%	-24.17%
Precigen	-3,084.55%	-90.99%	-67.26%

Does the media prefer CLLS or PGEN?

In the previous week, Cellectis and Cellectis both had 2 articles in the media. Precigen's average media sentiment score of 0.62 beat Cellectis' score of 0.20 indicating that Precigen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Precigen	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer CLLS or PGEN?

Precigen received 27 more outperform votes than Cellectis when rated by MarketBeat users. Likewise, 67.24% of users gave Precigen an outperform vote while only 66.23% of users gave Cellectis an outperform vote.

Company	Underperform	Outperform
Cellectis	Outperform Votes 406 66.23%	Underperform Votes 207 33.77%
Precigen	Outperform Votes 433 67.24%	Underperform Votes 211 32.76%

Which has more risk and volatility, CLLS or PGEN?

Cellectis has a beta of 3.09, suggesting that its share price is 209% more volatile than the S&P 500. Comparatively, Precigen has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500.

Do analysts prefer CLLS or PGEN?

Cellectis currently has a consensus target price of $8.00, suggesting a potential upside of 322.39%. Precigen has a consensus target price of $7.00, suggesting a potential upside of 677.78%. Given Precigen's higher possible upside, analysts clearly believe Precigen is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00
Precigen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Which has stronger valuation & earnings, CLLS or PGEN?

Precigen has lower revenue, but higher earnings than Cellectis. Precigen is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$13.03M	8.08	-$101.06M	-$1.29	-1.47
Precigen	$4.39M	51.76	-$95.90M	-$0.39	-2.31

Summary

Precigen beats Cellectis on 9 of the 17 factors compared between the two stocks.